- Home
- SACH vs CRVO Comparison
SACH vs CRVO Comparison
Compare SACH & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- CRVO
- Stock Information
- Founded
- SACH 2010
- CRVO 2001
- Country
- SACH United States
- CRVO United States
- Employees
- SACH N/A
- CRVO N/A
- Industry
- SACH Real Estate Investment Trusts
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- CRVO Health Care
- Exchange
- SACH Nasdaq
- CRVO Nasdaq
- Market Cap
- SACH 61.5M
- CRVO 67.4M
- IPO Year
- SACH 2017
- CRVO N/A
- Fundamental
- Price
- SACH $1.17
- CRVO $8.42
- Analyst Decision
- SACH Hold
- CRVO Strong Buy
- Analyst Count
- SACH 4
- CRVO 7
- Target Price
- SACH $2.25
- CRVO $19.33
- AVG Volume (30 Days)
- SACH 191.7K
- CRVO 179.2K
- Earning Date
- SACH 08-13-2025
- CRVO 08-08-2025
- Dividend Yield
- SACH 17.17%
- CRVO N/A
- EPS Growth
- SACH N/A
- CRVO N/A
- EPS
- SACH N/A
- CRVO N/A
- Revenue
- SACH N/A
- CRVO $9,308,215.00
- Revenue This Year
- SACH N/A
- CRVO N/A
- Revenue Next Year
- SACH $4.52
- CRVO N/A
- P/E Ratio
- SACH N/A
- CRVO N/A
- Revenue Growth
- SACH N/A
- CRVO 15.14
- 52 Week Low
- SACH $0.80
- CRVO $1.80
- 52 Week High
- SACH $2.75
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- SACH 51.72
- CRVO 55.58
- Support Level
- SACH $1.14
- CRVO $7.25
- Resistance Level
- SACH $1.35
- CRVO $8.20
- Average True Range (ATR)
- SACH 0.06
- CRVO 0.55
- MACD
- SACH -0.01
- CRVO 0.19
- Stochastic Oscillator
- SACH 23.81
- CRVO 72.10
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.